CEO Choon-Peng Ng and Vice President of Innovation, Michael Fehlings, Ph.D., will discuss Asia’s role in the “golden age” of biotech and AI in therapeutics
SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that members of its executive team will present at two upcoming conferences, BioCentury-BayHelix East-West Summit 2024 and The State of Precision Medicine 2024.
Here is the upcoming event schedule:
To learn more about ImmunoScape and other upcoming events, visit the website.
About ImmunoScape
ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.
Contacts
Media:
Kalyn Schieffer for ImmunoScape
kos@anzupartners.com
NEW YORK, LONDON & MUMBAI--(BUSINESS WIRE)--$WNS #AnnualReport--WNS (Holdings) Limited (NYSE: WNS), a leading provider of…
CLEVELAND--(BUSINESS WIRE)--Cleveland-Cliffs Inc. (NYSE: CLF) today applauded the International Trade Commission’s (ITC) unanimous decision to…
NEW YORK--(BUSINESS WIRE)--#D2C--A year since its launch under Incredible Indriya, Eze Perfumes, the first direct-to-consumer…
DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Wind-Assisted Propulsion Market: Focus on Application, Technology, Installation Type, Vessel Type, and…
SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group”,…
DUBAI, United Arab Emirates & BENGALURU, India--(BUSINESS WIRE)--$WIPRO #APMEA--Wipro Limited (NYSE: WIT, BSE: 507685, NSE:…